期刊文献+

抗痛风药非布索坦的合成 被引量:8

Synthesis of antipodagric febuxostat
原文传递
导出
摘要 目的合成抗痛风药非布索坦并优化其工艺。方法以对羟基苯腈为原料,经加成、环合、甲酰化、烃化、氰化、水解6步反应制得目标产物。结果目标化合物的结构经1H-NMR、MS和元素分析确证,总收率33%。结论与文献报道的工艺比较,新工艺操作简单,反应时间缩短,成本降低,适合工业化生产。 Aim To improve the synthesis of antipodagric febuxostat and to optimize its procedure.Methods Antipodagric febuxostat was prepared starting from 4hydroxybenzonitrile via addition,cyclization,formylation,alkylation,cyanation,and hydrolysis.Results The overall yield of target compound was 33%,and its structure was confirmed by 1H-NMR,MS and elementary analysis.Conclusion In comparison with the reported procedure,the new route is simple,economic,and suitable for industrial production.
出处 《中国药物化学杂志》 CAS CSCD 2010年第4期282-284,共3页 Chinese Journal of Medicinal Chemistry
关键词 抗通风药 非布索坦 合成 优化工艺 antipodagric febuxostat synthesis procedure improvement
  • 相关文献

参考文献9

二级参考文献44

  • 1张媛.抗痛风药Febuxostat[J].药学进展,2005,29(3):141-142. 被引量:8
  • 2YAMAMOTO T. Development of antihyperuricemic candidates[J]. Nippon Rinsho, 2003, 61 ( S1 ) : 209 - 212.
  • 3TAKANO Y, HASE-AOKI K, HORIUCHI H, et al. Selectivity of febuxostat, a novel nonpurine inhibitor of xanthine oxldase/xanthine dehydyogenase[J]. Life Sci, 2005, 76(16) : 1835 - 1847.
  • 4BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat compared with aUopurinol in patients with hyperurlcemia and gout [ J ]. N Engl J IVied, 2005, 353(23) :2450 - 2461.
  • 5BECKER M A, SCHUMACHER H R Jr, WORTMANN R L. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a 28-day, multicenter, phase Ⅱ, randomized, double-blind, placebo controlled dose-response clinical trial examining safety and efficacy in patients with gout [ J ]. Arthritis Rheum, 2005, 52(3) :916 - 923.
  • 6POHAR S, MURPHY G. Febuxostat for prevention of gout attacks [ J ]. Issues Emerg Health Technol, 2006, 87(8) : 1 - 4.
  • 7TAYLOR W :j, SCHUMACHER H R :Jr. Assessment of outcome in clinical trials of gout-a review of current measures [ :J ]. Rheumatology, 2007, 46 ( 12 ) : 1751 - 1756.
  • 8BRYAN T, EMMERSON M D. The treatment of gout[J]. Drug Ther, 1996, 334(7) : 445 - 451.
  • 9VERGE J P, ROFFEY P. Antiprotozoal thiazoles. 2- (5-nitro-2-thienyl)-thiazoles[J] .J Med Chem, 1975, 18(8) :794.
  • 10HE H M, CUSHMAN M. A versatile synthesis of 2- methoxyestradiol, an endogenous metabolite of estradiol which inhibits tubulin polymerization by binding to the colchicine binding site [ J ]. Bioorg Med Chem Lett, 1994, 4 (14) : 1725 - 1728.

共引文献45

同被引文献55

  • 1张媛.抗痛风药Febuxostat[J].药学进展,2005,29(3):141-142. 被引量:8
  • 2张荣华,陆芳,朱志良.噻唑环衍生物的合成[J].化学研究与应用,2006,18(2):186-188. 被引量:6
  • 3Hasegawa M, Komoriya K. Cyano compound and its production: JP6345724[P]. 1994-12-20.
  • 4Kitamura M. Method of producing polymorphic crystal of 2-(3- cyanl-4- isobutyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid: JP2003261548[P]. 2003-09-19.
  • 5Bisht M,Bist S S. Febuxostat:a novel agent for management of hyperuricemia in gout[ J ]. Indian J Chem, Sect B, 2011,73 (6) :597 - 600.
  • 6Kondo S, Fukushim H, Hasegawa M,et al. 2-Arylthiazole derivatives and pharmaceutical composition containing the same [ P. EP :0513379,1992 - 06 - 11.
  • 7Sorbera L A, Revel L, Rabasseda X, et al. TMX - 67 : treatment of gout and hyperuricemia xanthine oxidase inhibitor [ J 1. Drug Future ,2001,26( 1 ) :32 -38.
  • 8Minoshima T, Hiramatsu T. Preparation of 2 - ( 3-cyanophenyl thiazoles as pharmaceuticals for treatment of aout and hyperuricemia [ P]. JP : 10139770,1998 - 05 - 26.
  • 9Hesse S, Kirsch G. A rapid access to eoumarin derivatives ( using Vismeier-Haack and Suzuki cross-coupling reaction ) [ J . Tetrahedron Lett ,2002,43 (7) : 1213 - 1136.
  • 10Nandhakumar R, Suresh T, Caslistus Jude A L,et al. Synthesis antimicrobial activities and cytogenetie studies of newer diazepino quinoline derivatives via Vilsmeiere-Haack reaction[ J]. Eur J Med Chem ,2007,42 ( 8 ) : 1128 - 1136.

引证文献8

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部